Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3309-3317

  Li, Sheng An ^a,b   Lee, Wen Hui ^a   Zhang, Yun ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFOPERAZONE; CEFTAZIDIME; CYCLOPHOSPHAMIDE; DEXTRO OH CATH; DEXTRO OH CM6; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; OH CATH30; OH CM6; PEXIGANAN; PIPERACILLIN; POLYMYXIN B; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL MEMBRANE; BACTERIUM ISOLATE; CONTROLLED STUDY; CYTOPLASM; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD 50; LETHAL DOSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; CELLS, CULTURED; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HEMOLYSIS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84861165882     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06304-11     Document Type: Article

References (44)

1. Ahmad I, Perkins WR, Lupan DM, Selsted ME, Janoff AS. 1995. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim. Biophys. Acta 1237:109-114.
2. Anderson RC, Hancock RE, Yu PL. 2004. Antimicrobial activity and bacterial-membrane interaction of ovine-derived cathelicidins. Antimicrob. Agents Chemother. 48:673-676. (Pubitemid 38141743)
3. Bals R, Wilson JM. 2003. Cathelicidins-a family of multifunctional antimicrobial peptides. Cell. Mol. Life Sci. 60:711-720. (Pubitemid 36570762)
4. Bommineni YR, et al. 2007. Fowlicidin-3 is an alpha-helical cationic host defense peptide with potent antibacterial and lipopolysaccharideneutralizing activities. FEBS J. 274:418-428. (Pubitemid 46046651)
5. Braunstein A, Papo N, Shai Y. 2004. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob. Agents Chemother. 48:3127-3129. (Pubitemid 38989185)
6. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. (Pubitemid 40298223)
7. Brown KL, et al. 2011. Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J. Immunol. 186:5497-5505.
8. Byl B, et al. 2001. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur. J. Clin. Microbiol. Infect. Dis. 20:804-807. (Pubitemid 34020457)
9. Cirioni O, et al. 2006. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. 50:1672-1679.
10. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. M100-S19. CLSI, Wayne, PA.
11. Dartois V, et al. 2005. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 49:3302-3310. (Pubitemid 41060575)
12. Fischbach MA, Walsh CT. 2009. Antibiotics for emerging pathogens. Science 325:1089-1093.
13. Ge Y, et al. 1999. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43:782-788. (Pubitemid 29165740)
14. Giacometti A, et al. 2004. Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am. J. Respir. Crit. Care Med. 169:187-194. (Pubitemid 38114533)
15. Haines LR, et al. 2009. Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoS Negl. Trop. Dis. 3:e373.
16. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. (Pubitemid 44967479)
17. Hilpert K, Volkmer-Engert R, Walter T, Hancock RE. 2005. Highthroughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 23:1008-1012. (Pubitemid 41114036)
18. Hoffmann R, Bulet P, Urge L, Otvos L, Jr. 1999. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochim. Biophys. Acta 1426:459-467. (Pubitemid 29078561)
19. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273:3718-3724. (Pubitemid 28109800)
20. Lee JY, et al. 2008. Salt-resistant homodimeric bactenecin, a cathelicidinderived antimicrobial peptide. FEBS J. 275:3911-3920. (Pubitemid 351990953)
21. Leendertse M, et al. 2009. Neutrophils are essential for rapid clearance of Enterococcus faecium in mice. Infect. Immun. 77:485-491.
22. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P. 1991. Ultrasensitive assays for endogenous antimicrobial polypeptides. J. Immunol. Methods 137:167-173.
23. Lin QP, et al. 2008. Lipopolysaccharide neutralization by the antibacterial peptide CM4. Eur. J. Pharmacol. 596:160-165.
24. Lipnick RL, et al. 1995. Comparison of the up-and-down, conventional LD50, and fixed-dose acute toxicity procedures. Food Chem. Toxicol. 33:223-231.
25. Lipsky BA, Holroyd KJ, Zasloff M. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47:1537-1545.
26. Ludtke SJ, et al. 1996. Membrane pores induced by magainin. Biochemistry 35:13723-13728. (Pubitemid 26363914)
27. McGwire BS, Olson CL, Tack BF, Engman DM. 2003. Killing of African trypanosomes by antimicrobial peptides. J. Infect. Dis. 188:146-152. (Pubitemid 36829755)
28. Noto PB, et al. 2008. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 17:1249-1255. (Pubitemid 351930922)
29. Oyston PC, Fox MA, Richards SJ, Clark GC. 2009. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol. 58:977-987.
30. Pacor S, Giangaspero A, Bacac M, Sava G, Tossi A. 2002. Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. J. Antimicrob. Chemother. 50:339-348.
31. Rinaldi AC, et al. 2002. Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. Biochem. J. 368:91-100. (Pubitemid 35463412)
32. Sarig H, et al. 2010. A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J. 24:1904-1913.
33. Skerlavaj B, et al. 1996. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J. Biol. Chem. 271:28375-28381. (Pubitemid 26374655)
34. Thennarasu S, et al. 2010. Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys. J. 98:248-257.
35. Vaara M. 2009. New approaches in peptide antibiotics. Curr. Opin. Pharmacol. 9:571-576.
36. Wu M, Maier E, Benz R, Hancock RE. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38:7235-7242.
37. Yu PL, Cross ML, Haverkamp RG. 2010. Antimicrobial and immunomodulatory activities of an ovine proline/arginine-rich cathelicidin. Int. J. Antimicrob. Agents 35:288-291.
38. Zanetti M. 2004. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75:39-48. (Pubitemid 38166778)
39. Zanetti M, Gennaro R, Romeo D. 1995. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374:1-5.
40. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. (Pubitemid 34100944)
41. Zasloff M. 2007. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J. Am. Soc. Nephrol. 18:2810-2816. (Pubitemid 350058386)
42. Zhang L, et al. 2005. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49:2921-2927. (Pubitemid 40917611)
43. Zhang Y, et al. 2010. Structure-function relationship of king cobra cathelicidin. Peptides 31:1488-1493.
44. Zhao H, et al. 2008. Identification and characterization of novel reptile cathelicidins from elapid snakes. Peptides 29:1685-1691.